Teva boosts forecasts as sales of generics, Huntington's disease drug jump
Adds details from conference call in paragraphs 4,5,6 and 7; analyst comment in paragraph 15, graphic
By Bhanvi Satija and Michael Erman
July 31 (Reuters) -Teva Pharmaceutical Industries TEVA.N raised its annual forecasts on Wednesday, banking on strong demand for its cheaper copycat medicines, including a GLP-1 generic, and branded treatment for Huntington's disease.
The drugmaker has been looking to launch six biosimilars by 2027, which, along with its branded medicines, is expected to drive growth.
Teva's branded medicine trio includes Austedo for treating Huntington's disease, Ajovy for migraine and recently launched Uzedy for schizophrenia.
The company, which had launched its rheumatoid arthritis drug Simlandi — a close copy of AbbVie's ABBV.N blockbuster Humira — in the United States earlier this year, said it was pleased with the progress of the launch.
"We're well set for this (Simlandi) to generate some performance in third and fourth quarters of this year," CEO Richard Francis said on a post-earnings call.
Francis said Teva was also better prepared for the launch of psoriasis treatment Selarsdi, a biosimilar to Johnson & Johnson's JNJ.N Stelara, in the U.S. in February 2025.
Pharmacy benefit managers and insurers are "becoming more knowledgeable and have an increasing appetite for the benefit of biosimilars and that will play favorably for Stelara", Francis added.
The company's U.S.-listed shares, which have jumped 70% so far this year, were trading up about 9% at $17.86 — their highest level since February 2019.
U.S. sales for Teva's generic products — which make up nearly a quarter of the company's total revenue — rose about 16% in the second quarter on demand for its generic of Bristol Myers' BMY.N blood cancer drug Revlimid.
While Teva sees revenue from generic Revlimid slowing down later this year, it expects to minimize the impact of competition.
The drugmaker said liraglutide, a generic of Novo Nordisk's NOVOb.CO drug Victoza for patients with type 2 diabetes, also received a lot of attention and helped drive growth in the segment.
Teva's liraglutide injection, launched in June in the U.S., is the first GLP-1 generic to enter the market.
The company expects 2024 revenue to be between $16 billion and $16.4 billion, versus its previous range of $15.7 billion to $16.3 billion.
It also raised the lower end of its annual profit forecast to $2.30 per share from $2.20.
The second-quarter performance and the forecast raise imply Teva's improved underlying strength, said Jefferies analyst Glen Santangelo.
Teva's second-quarter profit of 61 cents per share beat LSEG estimates of 57 cents.
The company lifted its annual revenue forecast for Austedo by $100 million to about $1.6 billion.
U.S. sales of Teva's generic products & some branded drugs https://reut.rs/4c37I4l
Reporting by Bhanvi Satija in Bengaluru and Michael Erman in New Jersey; Editing by Shilpi Majumdar and Shinjini Ganguli
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
